Rimonabant or Acomplia is an
anorectic anti-obesity drug.
It will be sold by
Sanofi-Aventis under the trade name
Acomplia starting in 2006.
Rimonabant might also be effective as
an anti-addictive drug in the treatment of
alcoholism as well as nicotine and
stimulant addiction. Rimonabant is
a CB1 cannabinoid receptor antagonist.
Early
results of two Phase III studies with
ACOMPLIA? (rimonabant), the first in a new
class of therapeutics called Selective CB1
Blockers, indicate that overweight/obese
patients with untreated dyslipidemia (high
triglycerides and/or high total
cholesterol/HDL cholesterol ratio) lost
weight in one year while improving their
lipid and glucose profiles, and that
smokers who had previously unsuccessfully
tried to quit smoking, were able to quit
in 10 weeks without post cessation weight
gain. The results of both the RIO-Lipids
(Rimonabant In Obesity) and STRATUS-US (Studies
with Rimonabant And Tobacco Use) trials
were presented for the first time to the
scientific community at the American
College of Cardiology annual meeting in
New Orleans, LA.
Primal Defense Probiotic Info |
HairTransplant
|